Company Name Mersana Therapeutics
Mailing Address 840 Memorial Drive Cambridge, MA 02139 USA
Company Description Mersana Therapeutics, Inc. (formerly Nanopharma Corp.) is focused on developing novel oncology agents based on Fleximer, a stealth material that enhances the pharmacokinetics and safety of drugs.
Proceeds Purposes Mersana plans to use the proceeds to further develop its pipeline programs and expand its proprietary ADC platform. The Company currently anticipates filing an Investigational New Drug (IND) application for lead candidate XMT-1522, a novel HER-2 targeting therapy, in mid-2016, and plans to initiate a Phase 1 proof of concept clinical trial shortly thereafter. Mersana’s second program, XMT-1536, a novel anti-sodium-dependent phosphate transport protein 2B (anti-NaPi2b) ADC, is currently advancing into IND-enabling studies.